Boehringer Doubles Down On Deafness With Rinri Backing
Executive Summary
After making a move into hearing loss with an investment into Acousia Therapeutics, BI is backing a UK biotech which hopes to reverse neuropathic sensorineural hearing loss.
| Table |
|---|
Advertisement
Related Content
BI Inks Second Obesity Pact With Denmark’s Gubra
Boehringer Ingelheim Is Getting Bets In Early In IO Space
Protecting Against Hearing Loss: Acousia Pursues A New Approach
Topics
- Therapy Areas
- Ear, Nose & Throat
- Subjects
- StartUps and SMEs
- Regenerative Medicine
- Financing
- Commercial
- Industries
- BioPharmaceutical
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC125258
Ask The Analyst
Please Note: Click here for more information on the Ask the Analyst service.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC125258
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.